COVID-19

COVID-19 treatments: research and development

The European Medicines Agency (EMA) is interacting with developers of potential COVID-19 treatments to enable promising medicines to reach patients in the European Union (EU) as soon as possible.

EMA is providing guidance to assist developers of potential COVID-19 treatments to prepare for eventual applications for marketing authorisation

The outcome of any consultation or advice from EMA is not binding on developers.

COVID-19 treatments that have received EMA advice

ProductDeveloperTherapeutic class/drug typeDevelopment stage at time of guidance
A64-DPBCN Peptides SAImmunomodulatorNon-clinical phase
AcalabrutinibAcerta Pharma BV / AstraZenecaImmunomodulatorClinical phase
Anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulinAlliance hyperimmune project (Biotest AG, Bio Products Laboratory, LFB, Octapharma, CSL Behring and Takeda)AntiviralClinical phase
APN01Apeiron BiologicsImmunomodulatorClinical phase
ApremilastAmgen Europe BVImmunomodulatorClinical phase
AZD7442AstraZenecaAntiviral (monoclonal antibody)Non-clinical phase
BaricitinibEli LillyImmunomodulatorClinical phase
CD24FcOncoimmune IncImmunomodulatorClinical phase
CHAG-COVID19-CAChimAgentsChallenge agent for human infection modelsNon-clinical phase
ChloroquineOxford UniversityOther therapeuticsClinical phase
Chloroquine and hydroxychloroquine cyclops DPIPureIMSOther therapeuticsClinical phase
Copper chlorideACOMAntiviralClinical phase
CT-P59CelltrionAntiviral (monoclonal antibody)Non-clinical phase
DanoprevirAscletis Pharmaceuticals Co LtdAntiviralClinical phase
EculizumabAlexion

Immunomodulator

Clinical phase
Emapalumab and anakinraSwedish Orphan Biovitrum AB (SOBI)ImmunomodulatorClinical phase
FAV00BFarmak International Holding GmbHAntiviralNon-clinical phase
FavipiravirGlenmark Pharmaceuticals LtdAntiviralClinical phase
GimsilumabRoivantImmunomodulatorClinical phase
Kamada Anti-SARS-CoV-2Kamada Ireland LtdImmunoglobulinNon-clinical phase
Larifan Plus

Auramed Ltd

AntiviralNon-clinical phase
LY-CoV555 (LY3819253) and LY-CoV016 (LY3832479)Eli LillyAntiviral (monoclonal antibody)Non-clinical phase
M5049Merck HealthcareImmunomodulatorNon-clinical phase
MavrilimumabKiniksa PharmaceuticalsImmunomodulatorClinical phase
MeplazumabJiangsu Pacific Meinuoke Biopharmaceutical Co LtdAntiviral (monoclonal antibody)Clinical phase
MK-4482Ridgeback Biotherapeutics LP/Merck Sharp & Dohme (Europe) IncAntiviralNon-clinical phase
OtilimabGSKImmunomodulatorClinical phase
PF-07304814PfizerAntiviralNon-clinical phase
RaloxifeneDompéAntiviralNon-clinical phase
RavulizumabAlexionOther therapeuticsClinical phase
RBT-9Renibus Therapeutics IncAntiviralClinical phase
REGN10933, REGN10987, REGN10989Regeneron UKAntiviral (monoclonal antibody)Non-clinical phase
RemdesivirGileadAntiviralClinical phase
RESP301Thirty Respiratory Limited (30 Technology)AntiviralNon-clinical phase
SarilumabSanofi AventisImmunomodulatorClinical phase
SiltuximabEUSApharmaImmunomodulatorClinical phase
TocilizumabRocheImmunomodulatorClinical phase
UNI911Union TherapeuticsAntiviralClinical phase

2703
7831, VIR-7832

Vir Biotechnology/GSKAntiviral (monoclonal antibody)Clinical phase
SNG001

Synairgen Research Limited

ImmunomodulatorClinical phase
VRP-033Venus Pharma GmbHImmunomodulatorNon-clinical phase
BRII-196, BRII-198Brii BiosciencesAntiviral (monoclonal antibody)Non-clinical phase
SCTA01Sinocelltech Ltd.Antiviral (monoclonal antibody)Clinical phase
ItolizumabBiocon Biologics LimitedImmunomodulator (monoclonal antibody)Clinical phase
BI 764198Boehringer Ingelheim International GmbHOther therapeuticClinical phase
4P0214P-PharmaAntiviralNon-clinical phase
Masitinib mesylateAB ScienceAntiviralNon-clinical phase
EX-14870Boehringer Ingelheim International BmBHAntiviralNon-clinical phase
2DeoDermin Sp. Z.0.0Other therapeuticNon- Clinical Phase
EmiplacelBiopharma Excellence GmbHOther therapeuticClinical Phase
AT-527RocheAntiviralClinical phase
ABBV-47D11AbbVieAntiviralClinical phase
AviptadilRelief Therapeutics Holding S.AOther therapeuticsClinical Phase
AR-711Aridis Pharmaceuticals, Inc.Antiviral (monoclonal antibody)Non-clinical phase
ColchicinePharmascience Inc. (PMS) / Montreal Health Institute (MHI)ImmunomodulatorClinical Phase
CoviFabInmunova S.A. / mAbxienceAntiviralClinical phase
IgM enriched human immune globulin (Trimodulin) (BT588)Biotest AGAntiviralClinical phase
 
Last updated 28 February 2021.

This information should not be read as an endorsement of any medicine.

Ongoing clinical trials in the EU

Information on ongoing clinical trials for COVID-19 treatments in the European Economic Area (EEA) is available in the EU Clinical Trials Register (EU CTR):

Users can find information on:

  • phase II to phase IV adult clinical trials for COVID-19 treatments where the investigator sites are in the EEA;
  • any clinical trials in children with investigator sites in the EU and any trials that form part of a paediatric investigation plan, including those where the investigator sites are outside the EU.

Phase I clinical trials conducted solely in adults are not made publicly available in the EU CTR.

For more information on the EU CTR and how clinical trials are authorised and overseen in the EEA, see:

Topics

How useful was this page?

Add your rating
Average
1 rating
1 rating